ERBB2 and non-small cell lung carcinoma: Ongoing clinical trials DESTINY-Lung03 (NCT04686305) and the HUDSON trial (NCT03334617) are investigating the combination of T-DXd with immunotherapy, chemotherapy, novel anticancer agents and will hence shed more light on the approach in HER2 mutant subgroup NSCLC patients.